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1 |  INTRODUCTION
Cortisol is a steroid hormone which plays a major part in the 
body's metabolic reaction to stress—be it physiological: ill-
ness, injury, and trauma; or psychological: mental ill-health. 
Its more common effect is often described as the “flight 
or fight” response, which allows the body to react quickly 
to a perceived “threat.” Cortisol is secreted by the adrenal 
glands and it is a product of the complex interaction between 
the hypothalamus and pituitary glands in the brain and the 
adrenal glands, which are located at the top of each kid-
ney—known as the hypothalamic-pituitary-adrenal (HPA) 
axis (HPA axis, see Figure  1; DeMorrow,  2018; Sapolsky 
et  al.,  2000). Cortisol is released for many hours after en-
countering a stressor and once the required concentration of 
cortisol is achieved, the cortisol exerts negative feedback to 
the hypothalamus, returning systemic homeostasis (Kyrou 
et al., 2006; Walker, 2006).
The majority of bodily cells have cortisol receptors; 
therefore, it plays an important role in regulating and 
supporting the different functions in the body: cardio-
vascular, metabolic, homeostatic, cellular health, and the 
central nervous system and it also supports the developing 
fetus in pregnancy. For instance, glucocorticoid recep-
tors are manifest in the majority of bodily cells, and their 
function is anti-inflammatory and immunosuppressive. 
Mineralocorticoid receptors are produced in the adrenal 
cortex and are responsible for electrolyte and fluid balance. 
Hence, cortisol is a vital hormone that protects health and 
well-being having the qualities of being immunosuppres-
sive and anti-inflammatory (Bellavance & Rivest,  2014; 
Wamil & Seckl, 2007).
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Abstract
This review examines the stress hormone cortisol which plays an important role in 
regulating and supporting different bodily functions. Disruption in cortisol produc-
tion has an impact on health and this review looks at a wide range of papers where 
cortisol has been indicated as a factor in numerous chronic conditions—especially 
those which are classed as “noncommunicable diseases” (NCDs). Timely detection, 
screening, and treatment for NCDs are vital to address the growing problem of NCDs 
worldwide—this would have health and socioeconomic benefits. Interestingly, many 
of the papers highlight the pro-inflammatory consequences of cortisol dysregulation 
and its deleterious effects on the body. This is particularly relevant given the recent 
findings concerning COVID-19 where pro-inflammatory cytokines have been impli-
cated in severe inflammation.
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Cushing's syndrome (hypercortisolism) is caused by high 
levels of circulating cortisol (glucocorticoid), with individ-
uals presenting with weight gain in the face, abdomen, and 
chest; it also causes skin changes, mood swings, osteoporo-
sis, and high blood pressure (Kyrou et al., 2006; NHS; The 
Pituitary Foundation, 2018). The glucocorticoid excess typ-
ical of Cushing's syndrome can also lead to the development 
of diabetes mellitus (Barbot et  al.,  2018) Diabetes mellitus 
falls into the category of metabolic diseases (MDs) which 
will be discussed later in this review. In contrast, Addison's 
disease (primary adrenal insufficiency) is characterized by 
low cortisol levels. It is a serious autoimmune disease which 
causes damage to the adrenal glands. The onset of the dis-
ease is slow and therefore difficult to diagnose; symptoms 
include fatigue, muscle and weight loss, mood swings, 
and skin changes (National Institute for Health & Care 
Excellence, 2016; NHS).
Importantly, both high and low levels of cortisol, however, 
are indicated in other chronic conditions which will be dis-
cussed in this review.
Cortisol secretion follows a natural 24-hr cycle (see 
Figure 2). In healthy individuals, peak levels are reached about 
30 min after waking—this early peak is known as the cortisol 
awakening response (CAR). Levels decline throughout the 
day, with lowest levels occurring during the early sleeping 
phase (Clow et al., 2010; Fries et al., 2008). However, pro-
longed exposure to stressors can lead to the overstimulation 
of the HPA axis resulting in fluctuating cortisol levels. This 
dysregulation of the HPA axis and its resultant disruption of 
the 24-hr cycle have been the subject of several studies which 
seek to establish a link between cortisol levels and ill-health 
(Adam et al., 2017; Rao & Androulakis, 2018).
The World Health Organization (WHO) in its report 
“Mental health, resilience and inequalities” (Friedl, 2009) 
recognizes the role of low-level prolonged psychological 
stress in the hyperactivation of neuroendocrine, cardio-
vascular, and immunological systems. It highlights the 
link to cortisol production and how this is implicated in 
the development of chronic conditions such as coronary 
heart disease, stroke, diabetes, high blood pressure, MDs, 
and mental illness. The WHO states that these diseases, in 
which HPA axis dysregulation is indicated, form a part of a 
group of illnesses termed as “noncommunicable diseases” 
(NCDs)—cardiovascular disease (CVD) accounts for the 
majority of deaths with 17.9 million people dying annually, 
and diabetes accounts for 1.6 million deaths. The WHO 
highlights the need for timely detection, screening, and 
treatment to address the burgeoning issue of NCDs world-
wide (World Health Organisation,  2018). Consequently, F I G U R E  1  An overview of the HPA axis
F I G U R E  2  Circadian Cortisol 
Secretion Pattern (Lovallo &amp; 
Thomas, 2012)
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this review looks at studies in which cortisol has been 
identified as being a significant biomarker associated with 
various chronic conditions.
2 |  CARDIOVASCULAR DISEASE
Cardiovascular disease refers to conditions which affect 
the heart or blood vessels; these include coronary heart dis-
ease, strokes, peripheral arterial disease, and aortic disease 
(NHS). The majority of NCDs worldwide are the result of 
cardiovascular disease with 17.9 million people affected 
annually (World Health Organisation,  2018). In this sec-
tion, we look particularly at the role of cortisol in stroke 
and heart disease.
2.1 | Stroke
Stroke is a life-threatening condition that occurs when there 
is an interruption in the blood supply to the brain. There are 
two causes of stroke: ischemic (which accounts for 85% of all 
cases)—where a blood clot interferes with the blood supply; 
and hemorrhagic—where a blood vessel supplying blood to 
the brain ruptures (NHS).
Stroke is the second most common cause of death world-
wide—there are 6.7 million deaths each year. In the UK, 
there are over 100,000 strokes each year and there are 1.2 
million stroke survivors—two-thirds of whom are left with 
a permanent disability. The cost to the NHS and social care 
agencies of each stroke patient is approximately £45,000 over 
5 years (Stroke Association, 2017).
Stress-induced raised cortisol levels (hypercortisolemia) 
lead to the risk factors implicated in stroke pathology (raised 
blood cholesterol, triglycerides, blood sugar, and hyperten-
sion), with prolonged long-term stress affecting blood clot-
ting—blood becomes stickier, thus increasing the incidence 
of stroke (University of Rochester Medical Center, 2020).
Several studies (Christensen et  al.,  2003; Iranmanesh 
et  al.,  2017; Kwon et  al.,  2015; Olsson et  al.,  1992; Zi & 
Shau, 2013) have focused on the negative impact of hyper-
cortisolemia in poststroke recovery. A Chinese study (Zi 
& Shau,  2013) identifies cortisol as a significant prognos-
tic marker of functional outcome and death poststroke. The 
study reported elevated cortisol levels in acute ischemic 
stroke patients—there was also a correlation between in-
creased cortisol levels and stroke severity. The study attri-
butes the hypercortisolemia to stress induced by the stroke. 
These raised cortisol levels were also consistent with neuro-
logical and cognitive deficits and poor outcomes.
Slowik et al (Slowick et al., 2002) in their study also re-
corded raised cortisol levels in stroke patients and noted an 
absence of cortisol circadian variation. The study also points 
to the correlation between increased cortisol and poor out-
comes—with patients suffering from confusion, delirium, 
and depression. Cortisol levels were found to be raised sev-
eral months poststroke. Interestingly, the authors posit that 
the raised serum cortisol levels, rather than being solely a 
stress response per se, are indicative of an inflammatory re-
sponse, which is demonstrated by the presence of inflamma-
tory markers. Supporting this Tene et al (Tene et al., 2018) 
found that subjects with high bedtime cortisol levels dis-
played inferior memory and functioning, this is consistent 
with HPA axis dysregulation.
A critical literature review (Mitchell,  1997) also high-
lights the fact that HPA axis dysregulation is present in up 
to 40% of stroke patients. It draws attention to studies which 
suggest a correlation between large neurological lesions and 
hypercortisolemia, resulting in poor outcomes and progno-
ses. It postulates that sustained high levels of glucocorti-
coids have a deleterious effect on the brain and its ability to 
recover; it goes on to advocate the timely use of antigluco-
corticoids poststroke. Another study (Marklund et al., 2004) 
also supports these findings, that hypercortisolemia is indi-
cated in poor outcomes and mortality poststroke. However, 
they also report an increased mortality in poststroke patients 
with low cortisol levels (hypocortisolemia)—they attribute 
this to a dysfunction in glucocorticoid secretion which in 
turn affects homeostasis. They also point to the incidence 
of hypocortisolemia in septic shock and the role of supple-
mentary hydrocortisone therapy in such cases of adrenal 
insufficiency.
Barugh et al (Barugh et al., 2014) in their wide-ranging 
systematic review report that the majority of studies look-
ing at acute stroke patients found high cortisol levels in the 
first week poststroke; these higher levels were consistent with 
poststroke complications such as dependency, delirium, de-
pression, and mortality. A loss of diurnal variation in severe 
strokes, leading to greater severity of illness, was also found 
to be significant in many studies. It was also noted that the 
diurnal variation was not affected in those suffering a less 
severe stroke. The authors caution other causes of HPA axis 
dysregulation, such as aging, stress, neurodegenerative dis-
ease, and post-acute stroke brain injury. The authors conclude 
by highlighting the need for further research in this field.
The Stroke Association (Stroke Association, 2017) states 
that one-third of stroke survivors experience depression post-
stroke and over 50% suffer from anxiety in the 10 years fol-
lowing a stroke. Several studies (Kwon et al., 2015; Olsson 
et al., 1992) cite dysregulation of the HPA axis as a factor in 
poststroke depression (PSD). In particular, a reduced CAR 
has been recorded in depressed poststroke patients (2 months 
plus poststroke) and restoration of the HPA axis function 
may be beneficial to PSD patients leading to the alleviation 
of their depressive symptoms and improved quality of life 
(Kwon et al., 2015).
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2.2 | Heart disease
Prolonged periods of stress and the resulting exposure to raised 
cortisol levels have been shown to have a significant effect on 
heart health—leading to an increase in blood cholesterol, tri-
glycerides, blood sugar, blood pressure, and truncal obesity. 
These are all risk factors in heart disease which can lead to a 
build-up of plaque deposits in the arteries (atherosclerosis); this 
affects blood clotting making blood stickier thus increasing the 
risk of cardiovascular disease (University of Rochester Medical 
Center, 2020). The British Heart Foundation recognizes the in-
fluence of emotional stress on the biological processes involved 
in heart disease; they are conducting research investigating the 
role of cortisol in the disease process by looking at how cortisol 
regulates inflammation; in particular, they are interested in the 
possibility that overexposure to cortisol results in cells becom-
ing desensitized, resulting in vascular inflammation (British 
Heart Foundation, 2020).
Several studies (Brotman et al., 2007; Dekker et al., 2008) 
have linked the effects of stress with cardiovascular disease; 
Kumari et al (Kumari et al., 2011) assert that in response to 
psychological stress, dysregulation of the HPA axis occurs. 
They report flat slopes in salivary cortisol and raised evening 
cortisol levels as being a predictor of cardiovascular deaths in 
middle-aged adults.
Dekker et al (Dekker et al., 2008) assert that an increase 
in total cortisol correlates with the incidence of carotid artery 
plaques as found in vascular atherosclerosis. They also refer 
to the increasing evidence linking cortisol levels and inflam-
mation; like Slowik et al (Slowick et al., 2002), they point to 
the effect of glucocorticoids on the blood vessels and their 
role in inflammation. Ikeoka et al (Ikeoka et al., 2010) cite 
the role of adipose tissue which is linked to glucocorticoid 
production and its role in inflammation as a factor in car-
diovascular disease. Another study also highlights the del-
eterious role of glucocorticoids in the development of CVD 
(Walker, 2007). It states that glucocorticoid excess is a risk 
factor in CVD—especially in the occurrence and progression 
of vascular atherosclerosis.
Numerous studies have linked raised cortisol levels 
with an increased risk of cardiac events. One study (Yamaji 
et al., 2009) cites the measurement of cortisol, together with 
brain natriuretic peptide and aldosterone as a predictor of 
cardiac events in patients with heart failure. It suggests that 
there is a link between the levels of cortisol and oxidative 
stress—as oxidative stress activates the cortisol-mineralocor-
ticoid receptor. Kelly et al (Kelly et al., 1998) in their study 
link increased cortisol levels to hypertension—a causal fac-
tor in CVD. Whitworth et al (Whitworth et al., 2005) while 
highlighting the role of glucocorticoid-induced hypertension 
in Cushing's syndrome assert that hypercortisolemia may be 
a factor in up to 30% of cases of hypertension in the general 
population.
The studies cited show a clear link between stress and dys-
regulated cortisol levels, which is a significant factor in CVD.
3 |  METABOLIC DISEASE/TYPE 2 
DIABETES MELLITUS
World Health Organization statistics reveal that in 2016, 1.6 
million deaths were directly caused by diabetes and it was 
the seventh leading cause of death in 2016. The trajectory of 
incidences of diabetes is increasing—there were 108 million 
sufferers worldwide in 1980, this had increased markedly to 
422 million by 2014 (World Health Organisation). A recent 
study estimates this figure to be 500 million in 2018—with 
the greatest growth in low-income countries (Bradshaw-
Kaiser et al., 2008). Diabetes UK reports that in the UK alone, 
the number of people diagnosed with diabetes has more than 
doubled in the past 20 years—they predict that there will be 
more than 5 million cases by 2025. Over 90% of diabetes re-
ported in the UK is type 2 diabetes mellitus (T2DM). These 
patients are more at risk of developing other diseases such as 
retinopathy, strokes, heart disease, kidney disease, and am-
putations. Diabetes UK estimates the cost of treating diabetes 
at £10 billion per annum—this figure represents 10% of the 
NHS annual budget (Diabe tes.org.uk).
Metabolic disease and T2DM are viewed very much as 
“modern” diseases as they are deemed to be symptomatic 
of contemporary lifestyle choices—characterized by poor 
dietary habits and sedentary lifestyles—increasing vis-
ceral obesity (Bose et al., 2009; Parades & Ribeiro, 2013). 
Consequently, numerous studies have been undertaken that 
highlight the link between HPA axis activity and MD and 
T2DM (Bose et al., 2009; Joseph & Golden, 2018; Parades 
& Ribeiro,  2013; Rosmond,  2003). The HPA axis controls 
the production of glucocorticoid hormones, which originate 
in the adrenal cortex, and chronic glucocorticoid exposure is 
a factor in MD and T2DM. This reduces insulin sensitivity, 
which leads to a decrease in insulin secretion (Di Dalmazi 
et  al.,  2012). Obesity is characterized by visceral adipose 
tissue, which has high levels of glucocorticoid receptors 
(Musazaki et al., 2001).
Many studies reference the role of stress in HPA axis 
dysregulation and how this is expressed in terms of MD and 
T2DM (Bose et  al.,  2009; Di Dalmazi et  al.,  2012; Joseph 
& Golden, 2018; Parades & Ribeiro, 2013; Rosmond, 2003). 
Bose et al (Bose et al., 2009) highlight the role of stress and 
truncal obesity in MD and the role of HPA dysregulation 
in this process. They suggest that obesity is caused by the 
localized effect of cortisol metabolism on adipose tissue—
Cushing's syndrome being a case in point. Interestingly, they 
also refer to studies which point to the incidence of chronic 
inflammation in obesity and MD (Hotamisligil,  2006; Lee 
et  al.,  1988), where pro-inflammatory cytokines stimulate 
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the HPA axis. They also cite other studies where cortisol has 
been shown to decrease cytokine production (Lederbogen 
et al., 2011).
Other studies (Di Dalmazi et  al.,  2012; Parades & 
Ribeiro, 2013) look at hypercortisolemia and metabolic dys-
function. Paredes et al (Parades & Ribeiro, 2013), for exam-
ple, link chronic stress and HPA axis dysregulation and how 
this is expressed in truncal obesity and insulin resistance (see 
Figure  3). They also refer to the pro-inflammatory conse-
quences of this process—they claim that prolonged low-grade 
inflammation creates a “vicious cycle” where the prolonged 
stress stimulates the HPA axis. Di Dalmazi et al (Di Dalmazi 
et al., 2012) advocate further research, especially in the de-
velopment of anti-inflammatory drugs to address glucose 
metabolism.
Several studies have investigated the role of circadian 
cortisol levels in T2DM patients. One study (Lederbogen 
et  al.,  2011) highlights the role of HPA dysregulation in 
both type 1 diabetes (T1D) and T2DM and its role in insu-
lin resistance. They report a flattened circadian profile, with 
lower morning and higher evening levels. They posit that 
these merits further investigation to ascertain how HPA axis 
dysregulation is implicated in the control of glycemic levels. 
Similarly, Hackett et al (Hackett et  al.,  2014) also report a 
flattened cortisol slope in their findings. Bruehl et al (Bruehl 
et al., 2008) look particularly at the CAR and diurnal salivary 
profiles of T2DM patients; they also interestingly look at the 
link with hippocampal volume in the context of its role in 
HPA axis feedback regulation. They report a blunting of the 
CAR but a maintained diurnal pattern. They also report a re-
duction in hippocampal volume, which was consistent with 
the duration of T2DM and glycemic control.
The role of stress and the resulting HPA axis dysregula-
tion is indicated in both MD and T2DM as characterized by 
an increase in visceral adipose tissue and a decrease in insulin 
sensitivity.
4 |  INFLAMMATION/
AUTOIMMUNE
Normal glucocorticoid function plays an important role in 
inflammation—it works by reducing inflammation and has 
an immunological and metabolic effect. Prolonged exposure 
to high cortisol levels and the resulting HPA axis dysfunc-
tion interferes with the anti-inflammatory and immunologi-
cal processes. High circulating cortisol levels affect immune 
cells by binding to their receptors leading to the production of 
pro-inflammatory cytokines (Glaser & Kiecolt-Glaser, 2005; 
Lavretsky & Newhouse, 2012) resulting in inflammation and 
immune deficits and other metabolic consequences (such as 
MD, T2DM, Cushing's syndrome, and Addison's disease).
Inflammation is increasingly recognized as being a factor 
in many diseases. Numerous studies have cited the role of 
HPA axis dysregulation in diseases where inflammation is 
indicated.
F I G U R E  3  Putative mechanisms involved in GC release, visceral adipose tissue accumulation, and the pathogenesis of metabolic syndrome. 
Cortisol, the major glucocorticoid in humans, is secreted in response to stressful events under the control of the hypothalamic-pituitary-adrenal 
axis. Cortisol exerts several cellular and metabolic effects in adipocytes, eventually promoting visceral obesity and the development of metabolic 
syndrome. CRH – corticotropin-releasing hormone; ACTH – adrenocorticotropic hormone (Parades &amp; Ribeiro, 2013)
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Fibromyalgia syndrome (FS) is a long-term rheumatic 
condition in which sufferers experience muscular and mus-
culoskeletal pain with stiffness and localized tenderness at 
specific points in the body, and it also causes extreme fatigue. 
Studies have demonstrated a link between stress and pain—
in particular, they focus on the role of cortisol levels and 
point to HPA dysregulation as a possible causal agent of pain 
(Blackburn-Munro, 2004; Hanniabl & Bishop, 2013; McBeth 
et  al.,  2005). They posit that prolonged heightened stress 
leads to the blunting of the HPA axis response. In particular, 
the CAR was found to be reduced throughout the day (Doerr 
et al., 2016; Riva et al., 2010). Similarly, numerous studies 
have also highlighted the link between HPA dysregulation 
and the resulting inflammation and autoimmune response 
with chronic fatigue syndrome (CFS; Morris et  al.,  2017; 
Papadopoulos & Cleare, 2011; Powell et al., 2013; Silverman 
et al., 2010; Van den Eede et al., 2007).
The role of inflammation is also being looked at in terms 
of cognitive diseases. The Alzheimer's Society is studying 
the role of cortisol release and stress and its effects on the 
immune system in Alzheimer's diseases. It does caution that 
the picture is not a straightforward one and to this end, it is 
currently funding research looking at chronic stress as a risk 
factor in the development of AD with a view to the devel-
opment of drug therapies (www.alzhe imers.org.uk/research).
The COVID-19 (Severe Acute Respiratory Syndrome 
Coronavirus 2) pandemic also casts light on the role of 
cortisol in respect of inflammation and immune deficits. 
The disease progression is characterized by what has been 
described as a “cytokine storm”—the causes of which are 
multifactorial; this results in extreme inflammation and a se-
verely suppressed immune response (Hickman, 2020; Mehta 
et al., 2020). Isidori et al (Isidori et al., 2020) examine the 
efficacy of glucocorticoid treatment in COVID-19 patients 
with adrenal insufficiency.
In June 2020, the RECOVERY (Randomized Evaluation 
of COVid-19 thERapY) at the Nuffield Department of 
Medicine, University of Oxford established that dexameth-
asone, a corticosteroid used to treat inflammatory condi-
tions, improved the survival rates in patients who required 
(a) ventilation—deaths were reduced by one-third—and (b) 
oxygen only—deaths were reduced by one-fifth (University 
of Oxford, 2020).
Extreme physiological stress and the resulting HPA axis 
dysregulation are significant factors in numerous conditions 
where chronic inflammation is an important factor.
5 |  CONCLUSION
It has been demonstrated that cortisol is a useful but some-
what complex biomarker, especially in terms of chronic ill-
health, as exemplified by the numerous conditions outlined 
in this review. It is important to understand its function and 
systemic effects and how it links to other biochemical com-
ponents. The greater understanding of the complex relation-
ship between cortisol and chronic ill-health will enable the 
development of therapies.
The monitoring of cortisol levels would be advantageous 
in that it would facilitate timely diagnosis, monitoring, and 
prognosis—this would, in turn, allow for appropriate clinical 
planning, positive patient outcome, and allocation of health-
care resources. The World Health Organization, in particu-
lar, in relation to NCDs recognizes the importance of “early 
detection and timely treatment” and the positive impact of 
such interventions (World Health Organisation,  2018). The 
Royal Society for Public Health (Royal Society for Public 
Health, 2013) also points to the serious health and economic 
burden of NCDs and advocates for interventions which would 
lead to a reduction in the risk factors of developing such dis-
eases—the monitoring of cortisol levels could be one such 
significant intervention which would address the needs of the 
public health agenda.
To this end, the development of a rapid, point-of-care 
diagnostic test would be beneficial—it would not require 
trained personnel or a laboratory and could be used in sev-
eral settings: home, community, hospital, and suboptimal 
settings. This would facilitate more timely diagnoses and 
improved monitoring, thus advancing clinical outcomes and 
wellness. Patients could also self-monitor their cortisol lev-
els, giving them autonomy to manage their condition and 
freeing up clinicians.
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